Acute coronary syndrome in chronic kidney disease: clinical characteristics and stage-wise associations from a tertiary care centre in Western India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20262641Keywords:
Acute coronary syndrome, Cardiovascular disease, Chronic kidney disease, Left ventricular ejection fraction, NSTEMI, TroponinAbstract
Background: Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Acute coronary syndrome (ACS) in CKD is often associated with atypical presentations, diagnostic challenges and adverse outcomes. Data from western India regarding the clinical profile of CKD patients presenting with ACS remain limited.
Methods: This ambispective observational study was conducted at Goa Medical College, Goa. Adult patients with CKD presenting with ACS between September 2019 and August 2025 were included. Demographic characteristics, comorbidities, clinical presentation, cardiac biomarkers, echocardiographic findings and ACS subtype were assessed. Associations between CKD stage and clinical variables were analysed using the Chi-square test and analysis of variance.
Results: A total of 220 patients were included. The mean age was 66.5±9.1 years and 53.2% were male. Hypertension (87.3%), diabetes mellitus (71.8%) and dyslipidemia (66.8%) were common. NSTEMI was the predominant ACS subtype (60%), followed by unstable angina (37.7%) and STEMI (2.3%). Nearly half of patients (45.9%) had atypical presentation. Advancing CKD stage was significantly associated with NSTEMI/STEMI presentation (p<0.001), higher troponin variability (p=0.004), dialysis dependence (p=0.002), higher Killip class (p=0.002) and lower left ventricular ejection fraction (p<0.001).
Conclusions: ACS in CKD is characterised by a high burden of cardiovascular risk factors, frequent atypical presentation and predominance of NSTEMI. Advanced CKD is associated with greater cardiac dysfunction and more severe ACS manifestations, highlighting the need for early cardiovascular evaluation and intervention in this population.
References
Matsushita K, Van der Velde M, Astor BC, Woodward M, Levey AS, De Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association. Circulation. 2003;108(17):2154-69.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034-47.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150.
National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143-421.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-51.
Charytan DM, Wallentin L, Lagerqvist B, Spacek R, De Winter RJ, Stern NM, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009;4(6):1032-43.
Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet. 2016;388(10041):276-84.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JFE, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339-52.
Bangalore S, Maron DJ, O’Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020;382(17):1608-18.
Majmundar M, Kansara T, Doshi R, Kumar A. Acute coronary syndrome in chronic kidney disease: contemporary trends and outcomes. Cardiorenal Med. 2021;11(1):1-10.
Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States. Circulation. 2007;116(13):1465-72.
Gunsolus IL, Sandoval Y, Smith SW, Sexter A, Schulz K, Herzog CA, et al. Renal dysfunction influences the diagnostic and prognostic performance of high-sensitivity cardiac troponin I. Clin Chem. 2018;64(10):1427-36.
Twerenbold R, Wildi K, Jaeger C, Giménez MR, Reiter M, Reichlin T, et al. Optimal cutoff levels of more sensitive cardiac troponin in patients with renal dysfunction. Circulation. 2015;131(23):2041-50.
Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112-9.
House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, et al. Heart failure in chronic kidney disease: conclusions from a KDIGO Controversies Conference. Kidney Int. 2019;95(6):1304-17.
Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-73.
McCullough PA, Sandberg KR. Chronic kidney disease and sudden cardiac death: epidemiology and prevention. Nat Rev Nephrol. 2013;9(4):211-21.
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157-72.
Downloads
Published
How to Cite
Issue
Section
